Taysha Gene Therapies, Inc.

NASDAQ:TSHA

Biotechnology

Healthcare
$3.99 +1.53%

+$0.10 today

Market cap
$1.30B
Beta
1.18
P/E (TTM)
-17.7
EPS (TTM)
-$0.35
52W Low $2.25High $7.30

Volume 3.38M

Average 2.73M

TSHA Pre-Tax Margin

Income before tax as a percentage of revenue.

Taysha Gene Therapies, Inc.NASDAQ: TSHA

Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026

Pre-tax margin not reported for Q2 FY2026

Over 3 fiscal years it widened by 5520.0 pp.

Context

  • Pre-tax margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
—— QoQ
Last fiscal yearDec 2025
-1115.3%-43.6 pp YoY
LTMJun 2026
-2728.0%-1583.1 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year-43.6 pp——
3 years+5520.0 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-1115.3%
Year-over-year change
-43.6pp

Pre-Tax Margin vs competitors

How TSHA compares with its peers on the latest reported figures

  • TSHA's LTM Jun 2026 pre-tax margin of -2728.0% is the lowest of the 6 companies compared; the peer median is -182.3%.
  • Its year-over-year change of -1583.1 pp is the lowest of 5, against a peer median of -92.7 pp.
  • Over three fiscal years its change of +5520.0 pp compares with a peer median of +135.0 pp.
TSHA Competitors Peer median
Pre-Tax Margin for TSHA and competitors
Company Period LTM level YoY 3-year change
ABEOAbeona Therapeutics Inc.LTM Mar 2026455.6% —+4032.1 pp
SRPTSarepta Therapeutics, Inc.LTM Mar 20261.1% +8.5 pp+42.0 pp
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-182.3% +766943.8 pp+3271.0 pp
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-319.3% -193.8 pp-182.8 pp
RGNXREGENXBIO Inc.LTM Mar 2026-330.2% -229.6 pp+135.0 pp
TSHATaysha Gene Therapies, Inc.LTM Jun 2026-2728.0% -1583.1 pp+5520.0 pp
NGNENeurogene Inc.FY2025— ——
BNTCBenitec Biopharma Inc.FY2025— ——
RCKTRocket Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding TSHA) -182.3%-92.7 pp+135.0 pp

Competitors are the stored peer set for TSHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue02.5M15.45M8.33M9.77M
Cost of Revenue02.49M000
Gross Profit015K15.45M8.33M9.77M
Gross Margin—0.6%100.0%100.0%100.0%
Research & Development131.94M91.17M56.78M66M86.4M
Selling, General & Admin41.32M34.87M30.05M28.95M33.87M
Operating Expenses173.27M126.04M87.89M99.79M120.27M
Depreciation & Amortization492K2.49M1.37M1.25M1.15M
EBITDA(172.6M)(159.73M)(105.2M)(87.95M)(107.79M)
EBITDA Margin—-6384.1%-680.8%-1055.5%-1102.9%
Operating Income(173.27M)(126.03M)(72.44M)(91.46M)(110.5M)
Operating Margin—-5037.1%-468.8%-1097.6%-1130.6%
Interest Income172K249K3.57M6.94M9.22M
Interest Expense1.43M3.8M5M102K63K
Other Income / Expenses(1.26M)(39.99M)(39.13M)2.16M1.5M
Income Before Tax(174.52M)(166.01M)(111.57M)(89.3M)(109M)
Pre-Tax Margin—-6635.3%-722.1%-1071.6%-1115.3%
Income Tax Expense00000
Net Income(174.52M)(166.01M)(111.57M)(89.3M)(109M)
Net Margin—-6635.3%-722.1%-1071.6%-1115.3%
EPS (Basic)(4.64)(3.78)(0.96)(0.36)(0.34)
EPS (Diluted)(4.64)(3.78)(0.96)(0.36)(0.34)
Weighted Avg Shares37.65M43.95M116.12M250.13M319.71M
Weighted Avg Shares (Diluted)37.65M43.95M116.12M250.13M319.71M

Taysha Gene Therapies, Inc.

NASDAQ:TSHA

Intrinsic Alpha fair value

Locked

Current Price

$3.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.